D-Aspartic Acid
DAA
D-Aspartic acid (DAA) is an endogenous amino acid marketed as a natural "testosterone booster." The human evidence does not support that claim: a single early controlled trial in untrained/sedentary men reported a short-lived rise in luteinizing hormone (LH) and testosterone, but every subsequent randomized controlled trial in resistance-trained men found no increase in testosterone, no gain in muscle or strength, and at a 6 g/day dose an actual reduction in total and free testosterone plus a drop in estradiol. It is not a hepatotoxic anabolic steroid and does not suppress the HPTA the way exogenous androgens do, so it is comparatively low-acute-risk, but it is also largely ineffective for its intended purpose and may paradoxically lower androgens at higher doses. It is not a SERM and does not restart a suppressed axis. The main danger is not toxicity but misplaced reliance on an ineffective product and the possibility of dose-dependent testosterone suppression; anyone using it for suspected low testosterone or fertility problems should see an endocrinologist rather than self-treat.
Mechanism of action
Pharmacokinetics
Not well characterized in humans; DAA is an endogenous amino acid rather than a xenobiotic drug. In the one positive human trial serum testosterone rose by ~day 6-12 and had regressed toward baseline by day 3 after stopping, implying a short functional window and rapid clearance of any hormonal effect.
Any hormonal effect appears short-lived (days); in untrained men the testosterone rise was not sustained and declined after cessation, and in trained men no effect persisted over 2-12 weeks.
Oral (sodium D-aspartate salt or D-aspartic acid powder).
Metabolized by the endogenous enzyme D-aspartate oxidase (DDO); one RCT documented increased serum DDO activity with supplementation, consistent with induced enzymatic breakdown that may blunt sustained exposure. Presented for monitoring/washout context only, not for test evasion.
For monitoring and washout planning, not drug-test evasion.
Physiological & performance effects
- In sedentary/untrained men, a single controlled trial reported increased serum LH and total testosterone (~30-40%) after ~12 days of ~3 g/day sodium D-aspartate.
- In resistance-trained men, randomized controlled trials consistently found no increase in total or free testosterone, LH, GnRH, or estradiol.
- No improvement in muscle mass, cross-sectional area, or strength beyond that produced by resistance training itself.
- At 6 g/day, total and free testosterone were significantly reduced versus placebo in trained men; estradiol was also reduced ~16% over 12 weeks.
- Net practical effect in trained populations: ineffective as an ergogenic/anabolic aid, with a possible dose-dependent suppressive signal at higher intake.
Adverse effects by system
No cardiovascular adverse effects or blood-pressure/lipid changes have been reported in human trials; cardiovascular safety was not a formal endpoint, so absence of reported harm is not proof of safety. No adequate long-term human cardiovascular data.
No hepatotoxicity signal reported; DAA is a non-17-alpha-alkylated amino acid with no known mechanism of liver injury. Liver enzymes were not a primary endpoint in the trials, so data are limited but no signal exists.
Paradoxical/dose-dependent: at 6 g/day total and free testosterone were significantly reduced and estradiol fell ~16%; at 3 g/day no significant hormonal change; the only testosterone increase was transient and confined to untrained men. It does not cause the profound HPTA shutdown seen with exogenous androgens.
Directly relevant given androgen effects: no fertility benefit demonstrated in the trained-men RCTs, and the 6 g/day testosterone reduction is a theoretical concern for reproductive/androgenic function; no controlled human trial demonstrated harm to sperm parameters, but reproductive safety at higher doses is not established.
No systematically collected psychiatric adverse-effect data in the controlled trials. Anecdotal reports of irritability, anxiety, and headache circulate but are not substantiated by primary literature; because D-aspartate interacts with NMDA/glutamatergic signaling, a theoretical neuro-excitatory concern exists but is unproven, and no adequate human data address it.
No renal adverse effects reported in human trials; renal function was not systematically assessed. No adequate human data on high-dose or long-term renal safety.
No hematologic adverse effects reported; hematocrit/hemoglobin were not endpoints. No adequate human data.
No dermatologic adverse effects (e.g., acne) reported in human trials. No adequate data.
HPTA suppression & recovery
Suppression: Low/atypical — DAA is not an exogenous androgen and does not shut down the HPTA the way testosterone or anabolic steroids do. However, at 6 g/day it paradoxically lowered endogenous total and free testosterone and estradiol in trained men, which is the opposite of its marketed purpose.
Any hormonal changes observed were modest and appeared reversible on cessation in the short trials, but recovery has not been formally studied. DAA is not a post-cycle therapy agent and does not restart a suppressed axis; it should never be used in place of clinician-directed recovery. If you have symptoms of low testosterone, suppressed axis, or fertility concerns, defer to an endocrinologist for evaluation (LH, FSH, total/free testosterone, estradiol, prolactin) rather than self-managing. Single-SERM, clinician-supervised approaches — not supplements like DAA — are the appropriate framework for axis recovery, and that decision belongs to a physician.
Monitoring
Cadence: If used at all, obtain a baseline hormone panel before starting and re-check at ~4-6 weeks; discontinue and consult a clinician if androgens fall or symptoms develop. Anyone with suspected hypogonadism or infertility should be evaluated and monitored by an endocrinologist rather than self-monitoring.
- Worsening low-testosterone symptoms: reduced libido, erectile difficulty, fatigue, low mood
- Testicular changes or new fertility problems
- New or worsening irritability, anxiety, or persistent headache
- Any symptom prompting medical evaluation — stop and seek clinician review
Contraindications
- Reliance on DAA as a substitute for medical evaluation of hypogonadism, infertility, or suspected low testosterone — see an endocrinologist instead.
- Use as a purported post-cycle or HPTA-recovery agent — it is not effective for this and delays proper clinician-directed care.
- Higher-dose (6 g/day) use given the documented paradoxical reduction in testosterone and estradiol in trained men.
- Pregnancy, breastfeeding, and use by adolescents/children — no safety data; excluded from all trials.
- Any established psychiatric or neurological condition where glutamatergic/NMDA modulation could theoretically be a concern — no human safety data, discuss with a clinician.
- Use without informing a treating physician if being evaluated or treated for any hormonal or fertility disorder.
Interaction profile
- ContraindicatedWith DNP: Additive cardiovascular strain
Check a specific combination in the interaction checker.
Reducing harm & when to stop
- Set expectations honestly: controlled human trials show DAA does not raise testosterone or improve muscle/strength in trained men, and 6 g/day may lower testosterone — do not expect an anabolic benefit.
- Do not use DAA as a treatment for suspected low testosterone, infertility, or as post-cycle/axis-recovery therapy; these require an endocrinologist. Supplements are not a substitute for a hormone workup.
- If you choose to use it despite the weak evidence, avoid the higher (6 g/day) dose given the documented paradoxical suppression of testosterone and estradiol.
- Get a baseline hormone panel and recheck it; stop if androgen levels or symptoms worsen.
- Because DAA products are unregulated supplements, purity and dose accuracy are not guaranteed — another reason to involve a clinician and rely on bloodwork, not label claims.
- Stop and seek medical care for new or worsening low-testosterone symptoms, fertility changes, or persistent neuropsychiatric symptoms (irritability, anxiety, headache).
- Pregnant/breastfeeding people and adolescents should not use it — no safety data.
Citations (5)
Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.
- 01
A controlled human trial reported that ~3 g/day sodium D-aspartate for 12 days increased serum LH and testosterone in men, with the rise regressing after cessation; proposed mechanism is cGMP-mediated LH release in the pituitary and cAMP-mediated testosterone synthesis in Leydig cells.
- 02
In a randomized controlled trial, 3 g/day D-aspartic acid for 28 days combined with heavy resistance training produced no change in total/free testosterone, LH, GnRH, or estradiol and no anabolic or ergogenic effect; serum D-aspartate oxidase increased.
- 03
In a randomized trial of resistance-trained men, 6 g/day D-aspartic acid for 14 days significantly REDUCED total and free testosterone while 3 g/day had no significant hormonal effect.
- 04
In a 12-week randomized, double-blind, placebo-controlled trial in resistance-trained men, 6 g/day D-aspartic acid did not change basal testosterone, reduced estradiol by ~16%, and produced no improvement in strength or hypertrophy beyond training.
- 05
Mechanistic cell-line work shows D-aspartic acid stimulates Leydig-cell steroidogenesis only in concert with hCG, via increased StAR protein and delayed LH-receptor internalization, not as a standalone testosterone stimulus.
PreclinicalPMID 26122485 ↗
Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice